Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Phase 2 Recruiting
20 enrolled
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
Phase 2 Completed
26 enrolled 18 charts
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Phase 2 Completed
53 enrolled 15 charts
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
Phase 2 Terminated
25 enrolled 15 charts
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 2 Completed
93 enrolled 12 charts
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Completed
53 enrolled 8 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Phase 2 Completed
37 enrolled 8 charts
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Phase 2 Completed
23 enrolled 11 charts
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Phase 2 Completed
103 enrolled 6 charts
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Phase 2 Completed
77 enrolled 7 charts
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Phase 2 Completed
22 enrolled 5 charts
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Phase 2 Completed
48 enrolled 5 charts
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
51 enrolled 14 charts
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Terminated
9 enrolled 9 charts
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
71 enrolled 10 charts
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
27 enrolled
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
Phase 2 Unknown
52 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
Phase 2 Unknown
10 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Unknown
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
Phase 2 Completed
82 enrolled
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
99 enrolled
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Phase 2 Unknown
60 enrolled
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Phase 2 Unknown
25 enrolled
Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Phase 2 Withdrawn
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
Phase 2 Completed
111 enrolled
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
35 enrolled
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Phase 2 Completed
33 enrolled
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Phase 2 Completed
35 enrolled
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Phase 2 Completed
40 enrolled
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
72 enrolled
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
Phase 2 Completed
28 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Phase 2 Completed
37 enrolled
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
Phase 2 Completed
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
Phase 2 Completed
82 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 2 Terminated
46 enrolled